{"id":35553,"date":"2025-10-07T13:07:18","date_gmt":"2025-10-07T06:07:18","guid":{"rendered":"https:\/\/thaipropertynews.com\/feeds\/?p=35553"},"modified":"2025-10-07T13:07:18","modified_gmt":"2025-10-07T06:07:18","slug":"revolutionary-myopia-management-technology-expands-across-asia-kubota-glass-makes-global-debut-at-asean-international-optics-fair-bangkok-2025","status":"publish","type":"post","link":"https:\/\/thaipropertynews.com\/feeds\/?p=35553","title":{"rendered":"Revolutionary Myopia Management Technology Expands Across Asia &#8212; Kubota Glass Makes Global Debut at ASEAN International Optics Fair Bangkok 2025"},"content":{"rendered":"<p><span class=\"legendSpanClass\"><span class=\"xn-location\">TOKYO<\/span><\/span>, <span class=\"legendSpanClass\"><span class=\"xn-chron\">Oct. 7, 2025<\/span><\/span> \/PRNewswire\/ &#8212; Kubota Pharmaceutical Holdings Co., Ltd. (TSE: 4596) today announced that its groundbreaking myopia management device, <b>Kubota Glass<\/b>, will make its international debut at ASEAN International Optics Fair Bangkok 2025, taking place in <span class=\"xn-location\">Bangkok, Thailand<\/span>, from <span class=\"xn-chron\">October 9-11, 2025<\/span>.<\/p>\n<div class=\"PRN_ImbeddedAssetReference\">\n<p> <a href=\"https:\/\/mma.prnasia.com\/media2\/2787763\/image.html\" target=\"_blank\" rel=\"nofollow\"> <img decoding=\"async\" src=\"https:\/\/mma.prnasia.com\/media2\/2787763\/image.jpg?p=medium600\" title=\"\" alt=\"\" \/> <\/a> <br \/><span><\/span><\/p>\n<\/div>\n<p><b>Addressing <span class=\"xn-location\">Asia&#8217;s<\/span> Myopia Crisis<\/b><\/p>\n<p>With half of the world&#8217;s population projected to become myopic by 2050, childhood myopia progression has emerged as a critical public health challenge, particularly across <span class=\"xn-location\">Asia<\/span> where prevalence rates are among the highest globally. Current treatment options remain limited, creating an urgent need for innovative, effective solutions.<\/p>\n<p><b>Breakthrough AR \u00d7 Optical Technology<\/b><\/p>\n<p>Kubota Glass represents a paradigm shift in myopia management through its proprietary <b>AR \u00d7 optical technology<\/b>, which projects actively stimulated defocus onto the retina to suppress myopia progression. The device is engineered for maximum convenience and compliance, requiring <b>only two hours of daily wear<\/b> while maintaining rigorous safety standards in full compliance with ISO regulations.<\/p>\n<p>&#8220;This technology has the potential to transform how we approach myopia management globally,&#8221; said Dr. <span class=\"xn-person\">Ryo Kubota<\/span>, President and CEO of Kubota Pharmaceutical Holdings. &#8220;Our pilot studies have demonstrated remarkable outcome, and we&#8217;re excited to bring this innovation to the Asian market where the need is most acute.&#8221;<\/p>\n<p><b>Innovative Design Features<\/b><\/p>\n<p>Kubota Glass incorporates several breakthrough features that set it apart in the myopia management landscape:<\/p>\n<ul type=\"disc\">\n<li><b>Ultra-lightweight design at just 40g<\/b> for comfortable daily use<\/li>\n<li><b>Smart monitoring capabilities<\/b> to track usage and treatment compliance<\/li>\n<li><b>Non-invasive approach<\/b> offering an alternative to daily eye drops<\/li>\n<li><b>ISO 15004-2 certified safety standards<\/b> for ophthalmic instruments<\/li>\n<li><b>Convenient 2-hour daily wear<\/b> fitting busy family schedules<\/li>\n<\/ul>\n<p>Small-scale pilot studies in <span class=\"xn-location\">the United States<\/span> and <span class=\"xn-location\">Taiwan<\/span> have shown encouraging preliminary results, including a high responder rate of up to 92%, with ongoing research continuing to evaluate the device&#8217;s long-term efficacy and safety profile.<\/p>\n<p><b>Strategic Asian Market Entry<\/b><\/p>\n<p>The <span class=\"xn-location\">Bangkok<\/span> exhibition will provide ophthalmologists, optical retailers, and optometrists from across ASEAN\u2014including <span class=\"xn-location\">Singapore<\/span>, <span class=\"xn-location\">Malaysia<\/span>, <span class=\"xn-location\">Taiwan<\/span>, <span class=\"xn-location\">the Philippines<\/span>, <span class=\"xn-location\">Vietnam<\/span>, and Indonesia\u2014with exclusive hands-on experience with Kubota Glass technology.<\/p>\n<p>Early adoption of Kubota Glass represents not only a solution to meet growing patient needs, but also a significant competitive advantage for eye care professionals in rapidly growing optical and ophthalmic markets.<\/p>\n<p>The company is committed to accelerating its expansion throughout <span class=\"xn-location\">Asia<\/span> through strategic partnerships and comprehensive practitioner support.<\/p>\n<p><b>About Kubota Pharmaceutical Holdings<\/b><\/p>\n<p>Kubota Pharmaceutical Holdings Co., Ltd. and its subsidiary, Kubota Vision Inc., are dedicated to translating innovation into a comprehensive portfolio of pharmaceutical and medical device solutions that preserve and restore vision for millions worldwide. Under the mission of &#8220;Innovation for Vision,&#8221; the company focuses on developing next-generation ophthalmic technologies, including advanced myopia management solutions, contributing to improved quality of life globally.<\/p>\n<p>For more information about Kubota Glass and the company&#8217;s vision care portfolio, visit <a href=\"http:\/\/www.kubotaholdings.co.jp\/en\/index.html\" target=\"_blank\" rel=\"nofollow\">www.kubotaholdings.co.jp\/en\/index.html<\/a><\/p>\n<p>\u00a0<\/p>","protected":false},"excerpt":{"rendered":"<p><!-- wp:html --><\/p>\n<p><span class=\"legendSpanClass\"><span class=\"xn-location\">TOKYO<\/span><\/span>, <span class=\"legendSpanClass\"><span class=\"xn-chron\">Oct. 7, 2025<\/span><\/span> \/PRNewswire\/ &#8212; Kubota Pharmaceutical Holdings Co., Ltd. (TSE: 4596) today announced that its groundbreaking myopia management device, <b>Kubota Glass<\/b>, will make its international debut at ASEAN International Optics Fair Bangkok 2025, taking place in <span class=\"xn-location\">Bangkok, Thailand<\/span>, from <span class=\"xn-chron\">October 9-11, 2025<\/span>.<\/p>\n<div class=\"PRN_ImbeddedAssetReference\">\n<p> <a href=\"https:\/\/mma.prnasia.com\/media2\/2787763\/image.html\" target=\"_blank\" rel=\"nofollow\"> <img decoding=\"async\" src=\"https:\/\/mma.prnasia.com\/media2\/2787763\/image.jpg?p=medium600\" title=\"\" alt=\"\" \/> <\/a> <br \/><span><\/span><\/p>\n<\/div>\n<p><b>Addressing <span class=\"xn-location\">Asia&#8217;s<\/span> Myopia Crisis<\/b><\/p>\n<p>With half of the world&#8217;s population projected to become myopic by 2050, childhood myopia progression has emerged as a critical public health challenge, particularly across <span class=\"xn-location\">Asia<\/span> where prevalence rates are among the highest globally. Current treatment options remain limited, creating an urgent need for innovative, effective solutions.<\/p>\n<p><b>Breakthrough AR \u00d7 Optical Technology<\/b><\/p>\n<p>Kubota Glass represents a paradigm shift in myopia management through its proprietary <b>AR \u00d7 optical technology<\/b>, which projects actively stimulated defocus onto the retina to suppress myopia progression. The device is engineered for maximum convenience and compliance, requiring <b>only two hours of daily wear<\/b> while maintaining rigorous safety standards in full compliance with ISO regulations.<\/p>\n<p>&#8220;This technology has the potential to transform how we approach myopia management globally,&#8221; said Dr. <span class=\"xn-person\">Ryo Kubota<\/span>, President and CEO of Kubota Pharmaceutical Holdings. &#8220;Our pilot studies have demonstrated remarkable outcome, and we&#8217;re excited to bring this innovation to the Asian market where the need is most acute.&#8221;<\/p>\n<p><b>Innovative Design Features<\/b><\/p>\n<p>Kubota Glass incorporates several breakthrough features that set it apart in the myopia management landscape:<\/p>\n<ul type=\"disc\">\n<li><b>Ultra-lightweight design at just 40g<\/b> for comfortable daily use<\/li>\n<li><b>Smart monitoring capabilities<\/b> to track usage and treatment compliance<\/li>\n<li><b>Non-invasive approach<\/b> offering an alternative to daily eye drops<\/li>\n<li><b>ISO 15004-2 certified safety standards<\/b> for ophthalmic instruments<\/li>\n<li><b>Convenient 2-hour daily wear<\/b> fitting busy family schedules<\/li>\n<\/ul>\n<p>Small-scale pilot studies in <span class=\"xn-location\">the United States<\/span> and <span class=\"xn-location\">Taiwan<\/span> have shown encouraging preliminary results, including a high responder rate of up to 92%, with ongoing research continuing to evaluate the device&#8217;s long-term efficacy and safety profile.<\/p>\n<p><b>Strategic Asian Market Entry<\/b><\/p>\n<p>The <span class=\"xn-location\">Bangkok<\/span> exhibition will provide ophthalmologists, optical retailers, and optometrists from across ASEAN\u2014including <span class=\"xn-location\">Singapore<\/span>, <span class=\"xn-location\">Malaysia<\/span>, <span class=\"xn-location\">Taiwan<\/span>, <span class=\"xn-location\">the Philippines<\/span>, <span class=\"xn-location\">Vietnam<\/span>, and Indonesia\u2014with exclusive hands-on experience with Kubota Glass technology.<\/p>\n<p>Early adoption of Kubota Glass represents not only a solution to meet growing patient needs, but also a significant competitive advantage for eye care professionals in rapidly growing optical and ophthalmic markets.<\/p>\n<p>The company is committed to accelerating its expansion throughout <span class=\"xn-location\">Asia<\/span> through strategic partnerships and comprehensive practitioner support.<\/p>\n<p><b>About Kubota Pharmaceutical Holdings<\/b><\/p>\n<p>Kubota Pharmaceutical Holdings Co., Ltd. and its subsidiary, Kubota Vision Inc., are dedicated to translating innovation into a comprehensive portfolio of pharmaceutical and medical device solutions that preserve and restore vision for millions worldwide. Under the mission of &#8220;Innovation for Vision,&#8221; the company focuses on developing next-generation ophthalmic technologies, including advanced myopia management solutions, contributing to improved quality of life globally.<\/p>\n<p>For more information about Kubota Glass and the company&#8217;s vision care portfolio, visit <a href=\"http:\/\/www.kubotaholdings.co.jp\/en\/index.html\" target=\"_blank\" rel=\"nofollow\">www.kubotaholdings.co.jp\/en\/index.html<\/a><\/p>\n<p>\u00a0<\/p>\n<p><!-- \/wp:html --><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"rop_custom_images_group":[],"rop_custom_messages_group":[],"rop_publish_now":"initial","rop_publish_now_accounts":[],"rop_publish_now_history":[],"rop_publish_now_status":"pending","footnotes":""},"categories":[5,7],"tags":[],"class_list":["post-35553","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-cision-pr-newswire","category-cision-pr-newswire-en"],"_links":{"self":[{"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=\/wp\/v2\/posts\/35553","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=35553"}],"version-history":[{"count":0,"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=\/wp\/v2\/posts\/35553\/revisions"}],"wp:attachment":[{"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=35553"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=35553"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=35553"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}